Skip to main content

Pharma/Regulatory

EULAR Points to consider for the definition of D2M and TR #Psoriatic_Arthritis Presented by Dr Helena Marzo-Ortega at #EULAR2025 @RheumNow https://t.co/3LsJvSiXJV
Nelly ZIADE 🍀 @Nellziade( View Tweet )
#EULAR2025 Abstr#OP0041 FcRn-inhibition is showing consistency in #Sjogren. Last year it was Nipocalimab. This proof-of-concept study showed efgartigimod met its primary endpoint, the CRESS response. No difference in ESSPRI. Phase 3 UNITY is underway @RheumNow https://t.co/jw1i4FqkIh
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
#WIN in systemic sclerosis (SSc): -Ongoing trials now targeting multiple pathways. -CONQUEST platform may reshape research in Ssc and other autoimmune diseases. -Revised CRISS could replace single organ endpoints for approval. #EULAR2025 @RheumNow https://t.co/kxSeFb5lAU
Adela Castro @AdelaCastro222( View Tweet )
APEX study showed significant inhibition of structural damage progression with both dosing regimens (Q4W and Q8W) of GUS (IL-23i) in biologic-naïve pts with active PsA. Abstract #LB0010 #EULAR2025 @RheumNow https://t.co/QxYAPGB67v
Adela Castro @AdelaCastro222( View Tweet )
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its faculty.

Dr. John Cush @RheumNow( View Tweet )

Management of AAV: 1.High dose GC f/b reduced dose taper ‼️caution in pts w/severe renal dz and RTX induction. 2. RTX effective for induction and maintenance, best for relapses. 3.PLEX: in RPGN pts if accesible ⚠️ risk for infection. 4.Avacopan: for faster GC weaning. No https://t.co/kfZ4gM38KG
Adela Castro @AdelaCastro222( View Tweet )
Autologous CAR T cell production, administration and monitoring Dinesh Khanna @RheumNow #EULAR2025 https://t.co/zrXjxSCRgl
Antoni Chan MD (Prof) @synovialjoints( View Tweet )
Why do people not respond to psoriatic arthritis therapies? #EULAR2025 @RheumNow https://t.co/VGLN0R3TyY
David Liew @drdavidliew( View Tweet )
Which CAR-based strategies would you consider to treat severe refractory #SLE based on data presented at #EULAR2025? @RheumNow

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )

EULAR PtC for the definition of #TR (Trt Refractory) #Psoriatic_Arthritis #D2M 1️⃣ Failure >= 2 b/tsDMARDs 2️⃣ Problematic 3️⃣ Evidence of persistent disease (inflammation is mandatory) + 4️⃣ Exclude comorbidities, psychosocial factors, failure due to SE/CI #EULAR2025 @RheumNow https://t.co/8nx26mWX3C
Nelly ZIADE 🍀 @Nellziade( View Tweet )
@RheumNow When it comes to ORAL Surveillance and the 2025 EULAR recommendations, the same sensibility remains. Appropriate caution based on the RCT, despite observational data, but we’ll see what is yet to come. Plenty to watch this space for #EULAR2025 @RheumNow https://t.co/fIxHRGDFcK
David Liew @drdavidliew( View Tweet )
from Rituximab to BiTES to CAR T, always looking for deeper B cell depletion Safety data from CC312 CD19/CD3/CD28, a triple engager in refractory moderate-to-severe SLE So far so good but how far do we need to go? #EULAR2025 @RheumNow LB0007

Aurelie Najm @AurelieRheumo( View Tweet )

#EULAR2025 Abstr#LB0001 Phase 3 RCT of Deucravacitinib in psoriatic arthritis met endpoints (ACR20) over PBO at Week 16. Prespecified early radiographic was not significant but post-hoc (without imputed data) showed radiographic inhibition @RheumNow https://t.co/ORUBtUWH31
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
#EULAR2025 @eular_org update #Recommendations #Rheumatoid #Rx prof Smolen subtle diff between former guidelines MTX+GC 👇 D/C GCs rapidly 👇 If inadequate response 👇 Other csDMARDs are OUT ❎ ✅go to bDMARD or tsDMARD* TsDMARD after safety assessed @RheumNow RecommendatnII https://t.co/yUrLdk6Eg1
Janet Pope @Janetbirdope( View Tweet )
#EULAR2025 Abstr#POS1293 Our cohort study support non-medical switch from Rituximab originator to Biosimilar(RTX-B) or btw RTX-Bs in connective tissue disease. No difference in response/B-cell depletion pre- & post-switch.Only 10% stopped RTX at 5-year.Better than in RA @RheumNow https://t.co/ERPgwQ3gZB
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Nerandomilast: the new & improved nintedanib. Does it work for our rheum pts? Autoimmune subgroup of FIBRONEER-ILD (NEJM last month) - mortality benefit vs placebo (this is new) - well tolerated (minimal increase in diarrhoea vs placebo) One to watch #EULAR2025 LB0003 @RheumNow https://t.co/u8fIy7kkKW
David Liew @drdavidliew( View Tweet )
#EULAR2025 Abstr#LB0003 Post-hoc analyses of Phase 3 RCT: Nerandomilast (with or without Nintadenib combo) in sub-group patients with autoimmune #ILD reported similar lung efficacy and safety over PBO, in line with overall trial population. Diarrhoea was common AE @RheumNow https://t.co/fxRdflCi9W
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
In RCT of RA pts in remission/low disease activity, spacing ozoralizumab (next gen TNFi) or reducing MTX led to more flares vs continued tx; but most pts in remission at baseline maintained LDAS. Remission matters for subsequent Tx reduction. @RheumNow #EULAR2025 #LB0006

Mrinalini Dey @DrMiniDey( View Tweet )

#EULAR2025 Abstr#LB0004 Phase 2 RCT of first-in-class, Enpatoran, TLR7/8-i in active #SLE despite SOC (Cohort B) reported nominal improvement in BICLA but no dose-dependent response. Greater effects seen on active CLE, high IFN-GS or high dose GC. No major safety signal @RheumNow https://t.co/aX4ier0rAy
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty.

Dr. John Cush @RheumNow( View Tweet )

Enpatoran (TLR7/8 inhibitor) in SLE & CLE - helps skin, others? - suppresses interferon lowest dose was highest response though (upsetting primary endpoint) Promising, watch for the ph3 No photos allowed, but official slides: https://t.co/1yX6XrYvKH #EULAR2025 LB0004 @RheumNow

David Liew @drdavidliew( View Tweet )

APEX study Ph3 RCT Guselkumab In BioNaive active PsA w/ erosions>=2 wk 24 ACR20 GUS Q4W 67% Q8W 68% vs PBO 47% Less Rx progression in both Q4W & Q8W vs. PBO #EULAR2025 @RheumNow LB0010 https://t.co/OVDWWECtOZ
Aurelie Najm @AurelieRheumo( View Tweet )
#EULAR2025 Abstr#LB0005 Phase IIb RCT in moderate #Sjogren reported significant reduction in ESSDAI at WK24 from BL in HCQ-Leflunomide vs PBO. CRESS & STAR improved. No significant difference in UWS, Schirmer, & ESSPRI. Future work: cohort of high symptom burden @RheumNow

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )

🦵🏻SAP-001, a novel uricosuric targeting a non-URAT1 renal transporter, lowered sUA <6 mg/dL in up to 79% of patients with refractory #gout on b/g xanthine oxidase inhibitor. >50% on 60 mg/day reached sUA <3 mg/dL. 💊Potential new oral ULT option. @RheumNow #EULAR2025 #LB0008 https://t.co/dfY1V5sHSh
Mrinalini Dey @DrMiniDey( View Tweet )
EULAR PtC for definition of #TR Trt Refractory) #Psoriatic_Arthritis #D2M 1️⃣ Failure >= 2 b/tsDMARDs 2️⃣ Problematic 3️⃣ Evidence of persistent dis + 4️⃣ Exclude drivers like comorbidities & psychosocial factors 🔺️Exclude failure due to Side Effets/CI #EULAR2025 @RheumNow https://t.co/ULD2Xe6p6A
Nelly ZIADE 🍀 @Nellziade( View Tweet )
×